These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 33599682)

  • 1. FDA's commitment to transparency.
    Guharoy R; Krenzelok E
    Am J Health Syst Pharm; 2021 Aug; 78(17):1550-1551. PubMed ID: 33599682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA's decision on Plan B: a surrogate for lack of commitment to women's health.
    Merkatz RB
    J Womens Health (Larchmt); 2005 Nov; 14(9):860. PubMed ID: 16313214
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA's post-approval studies continue to suffer delays and setbacks.
    Willyard C
    Nat Med; 2014 Nov; 20(11):1224-5. PubMed ID: 25375913
    [No Abstract]   [Full Text] [Related]  

  • 6. Accelerated Approval - Taking the FDA's Concerns Seriously.
    Sachs RE; Donohue JM; Dusetzina SB
    N Engl J Med; 2022 Jul; 387(3):199-201. PubMed ID: 35793197
    [No Abstract]   [Full Text] [Related]  

  • 7. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 8. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FDA's definitions, designations, and drug approvals: too daring?
    The Lancet Haematology
    Lancet Haematol; 2018 Aug; 5(8):e321. PubMed ID: 30075830
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA's Flexibility in Subpart H Approvals: Assessing Quantum of Effectiveness Evidence.
    Sasinowski FJ; Varond AJ
    Food Drug Law J; 2016 Aug; 71(1):135-157. PubMed ID: 29693934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA's Dunham delves into drug issues.
    Dunham B; Kahler SC
    J Am Vet Med Assoc; 2014 Apr; 244(7):762-3. PubMed ID: 24783315
    [No Abstract]   [Full Text] [Related]  

  • 12. Caution urged over the FDA's new breakthrough designation.
    Jiang K
    Nat Med; 2013 Oct; 19(10):1196. PubMed ID: 24100969
    [No Abstract]   [Full Text] [Related]  

  • 13. The FDA's defensive status and how it affects patient care.
    Yarows SA
    Arch Intern Med; 2011 Jul; 171(13):1217. PubMed ID: 21747025
    [No Abstract]   [Full Text] [Related]  

  • 14. Inappropriate obstructions to access: the FDA's handling of plan B.
    Wood SF
    Virtual Mentor; 2014 Apr; 16(4):295-301. PubMed ID: 24735580
    [No Abstract]   [Full Text] [Related]  

  • 15. The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016.
    Hwang TJ; Darrow JJ; Kesselheim AS
    JAMA; 2017 Dec; 318(21):2137-2138. PubMed ID: 29209711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preserve the FDA's authority.
    Guharoy R
    Am J Health Syst Pharm; 1996 Nov; 53(21):2636, 2638. PubMed ID: 8913395
    [No Abstract]   [Full Text] [Related]  

  • 17. Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs.
    Farrell AT; Goldberg KB; Pazdur R
    Blood; 2017 Sep; 130(11):1285-1289. PubMed ID: 28774876
    [No Abstract]   [Full Text] [Related]  

  • 18. Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways.
    Lynch HF; Bateman-House A
    J Law Med Ethics; 2020 Jun; 48(2):365-372. PubMed ID: 32631197
    [No Abstract]   [Full Text] [Related]  

  • 19. US FDA's safety monitoring of drugs with expedited approval.
    Furlow B
    Lancet Oncol; 2016 Mar; 17(3):281. PubMed ID: 26831290
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA's 'Accelerated Approvals' Are Critical But Raise Thorny Issues.
    Miller HI
    Mo Med; 2019; 116(3):168-169. PubMed ID: 31527930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.